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The impact of national prenatal screening
on the time of diagnosis and outcome of
pregnancies affected with common
trisomies, a cohort study in the Northern
Netherlands
Katelijne Bouman1, Marian K. Bakker1,2*, Erwin Birnie1, Lies ter Beek1, Caterina M. Bilardo2, Irene M. van Langen1
and Hermien E. K. de Walle1
Abstract
Background: To evaluate the impact of the introduction of prenatal screening on time of detection and pregnancy
outcome for trisomy 21 (T21), trisomy 18 (T18) and trisomy 13 (T13).
Methods: We performed a retrospective, population-based cohort study in the Northern Netherlands including 503
trisomy cases born between 2005 and 2012. Screening tests and invasive procedures, timing of diagnosis and pregnancy
outcome were compared between the period before (2005–2006) and after introduction (2007–2012) using X2 tests.
Results: There was an increase in proportion of women who had a prenatal screening and/or invasive test, from
62% in 2005–2006 to 84% in 2010–2012 (p < 0.01), while the proportion of prenatally diagnosed cases did not
change (60% overall). In women < =35 years 47% of the cases were diagnosed prenatally vs 73% in women >35 years
(p < 0.01). More T13/T18 cases were diagnosed <24 weeks after introduction (62% vs 84%; p < 0.01). In T13/T18
intra-uterine death decreased (26% vs 15%), while terminations increased: 55% vs 72%.
Conclusion: The introduction of prenatal screening had limited impact on the time of detection and outcome of
the most common trisomies. The introduction of the 20-week anomaly scan has resulted in more trisomy cases
diagnosed <24 weeks and a shift from fetal death to terminations.
Keywords: Prenatal screening, Trisomy 21, Trisomy 13, Trisomy 18, Maternal age, Pregnancy outcome
Background
The Netherlands have an exceptional position in Europe
when it concerns prenatal screening (PNS). Before 2007,
PNS for the common trisomies -trisomy 21 (T21), trisomy
18 (T18) and trisomy 13 (T13)- was based on advanced
maternal age of over 35 years (AMA). First and second
trimester PNS based on serum markers and/or nuchal
translucency (NT) were available, but only on request
of the pregnant woman [1]. A structural anomaly scan
(SAS) at 20 weeks gestation aimed at screening for con-
genital anomalies was not available nationwide. Scans
were only performed for dating and medical reasons
e.g., suspicion of intrauterine growth restriction or
excessive growth or a positive family history for fetal
anomalies.
Since January 2007, a nationwide prenatal screening
program has been implemented in the Dutch health care
system, in which the combined test (CT) in the first tri-
mester to determine the risk for T21 and a SAS for
neural tube defects in the second trimester are offered
to all pregnant women. In 2010 the CT expanded to
determine also the risk for T18 and T13. PNS is offered
after counselling and women are free to refrain from PNS.
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The Dutch Association of Obstetricians and Gynaecolo-
gists decided that not only the spine, but the entire fetus
should be examined. Ultrasound quality and knowledge of
the association between congenital anomalies or softmar-
kers and common trisomies has rapidly increased enabling
the use of SAS as an additional way of PNS for common
trisomies. Women over 35 years could also opt for direct
prenatal diagnosis through an amniocentesis or chorion
villous sampling. The costs of the CT were reimbursed for
this age category, whereas the younger women had to pay
for the CT themselves (approximately 160 Euros). The
SAS is reimbursed for all pregnant women.
Since the introduction of PNS for congenital anomalies
in other West European countries, more pregnancies are
terminated and fewer babies with common trisomies are
born alive in these countries [2–6]. A recent study from
Western Australia also found a significant reduction in
the rate of liveborns with Down syndrome [7]. The aim of
this study was to evaluate the impact of the implementa-
tion of PNS in the Northern Netherlands on the detection
of common trisomies: T21, T18 and T13 with respect to
both first and second trimester PNS, time of diagnosis
and pregnancy outcome. In addition we compared the
impact of the implementation of PNS on pregnancy
outcome for type of trisomy (T21 vs T13/T18) and for
women in two different age categories (<=35 years and
>35 years).
Methods
We performed a retrospective cohort study on cases
diagnosed with T21, T18 or T13, with a date of delivery
or termination of pregnancy (TOP) between 1-1-2005
and 31-12-2012 and for which the mother lived in one
of the three Northern provinces at the time of birth.
Cases diagnosed prenatally or postnatally with T21,
T18 or T13 were identified from the database of the
cytogenetic laboratory for three tertiary feto-maternal
units for prenatal diagnosis held at the University Medical
Centre of Groningen (UMCG). The cytogenetic laboratory
of the UMCG performs all pre- and postnatal karyotyping
in the Northern Netherlands. Standard trisomies,
Robertsonian translocations leading to a full T21, T18
or T13, T21, T18 or T13 mosaicisms and a diagnosis of
T21, T18 or T13 by quantitative fluorescence-polymerase
chain reaction (QF-PCR) or multiplex ligation-dependent
probe amplification (MLPA) in case of culture failure were
included. Partial T21, T18 and T13 due to a reciprocal
translocation were excluded. The database of the cyto-
genetic laboratory contains all genotyped cases of T21,
T18 or T13 diagnosed in the three Northern provinces.
Therefore the identification of cases with these com-
mon trisomies can be considered complete.
The first cohort contains cases born in 2005 and 2006,
from mothers that were not offered PNS on a routine
base. The second cohort contains cases born between
2007 and 2012, with a gestational age of at least 10 weeks
at January 1st 2007, from mothers that were offered PNS
routinely as part of the nationwide screening program.
The information on PNS, prenatal diagnosis and preg-
nancy outcome was retrieved from matching data from
the regional prenatal screening database, the prenatal
ultrasound database from the fetal medicine unit of the
UMCG and the regional congenital anomaly registry
EUROCAT Northern Netherlands.
Prenatal screening
For each case included in the study population, we re-
corded whether any form of PNS was performed regardless
of the trimester and independently of the outcome of PNS.
Prenatal screening in the first trimester (PNS1) was
defined as performed, if a risk assessment for T21 was
carried out based on more than maternal age only. In
the 2005–2006 cohort, risk assessment was occasionally
performed on the basis of either serum markers or nuchal
translucency. We defined these cases as “first trimester
PNS performed”, as the aim of the test was to estimate the
risk for T21. In the 2007–2012 cohort PNS1 was defined
as the combined risk assessment for T21 based on serum
free beta human chorionic gonatropin (fβ HCG), serum
pregnancy associated plasma protein A (PAPP-A), an NT
measurement and maternal age using the formulas of
the fetal medicine foundation. A high proportion of the
fetuses with T18 and T13 is detected with the T21
algoritm as well [8–10].
Second trimester PNS (PNS2) was defined as per-
formed if a second trimester SAS or a second trimester
serum PNS with serum markers HCG and AFP (alfa
fetoprotein) was accomplished. The aim of PNS by SAS
is to determine in an uncomplicated pregnancy the
presence of congenital anomalies or softmarkers, and
therefore can also be considered as a screening tool for
common trisomies.
Ultrasounds performed on parents request and without
medical indication and ultrasound scans performed for
dating or on medical indications (a priori risks, patholo-
gies suspected in the pregnancy etc.) were not considered
as PNS. Therefore, anomalies diagnosed “accidentally” in
these cases and followed by prenatal diagnosis (PND),
were considered diagnosis outside the PNS program.
AMA as such was not defined as a first nor as a second
trimester PNS tool for T21, T18 or T13.
Prenatal diagnosis
PND was defined as (molecular) karyotyping after
chorionic villus sampling (CVS) or amniocentesis (AC),
performed by licensed feto-maternal specialists in one
of the three tertiary feto-maternal units in the Northern
Netherlands. A CVS or an AC could be performed
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following first or second PNS, in mothers of AMA, or in
pregnancies in which anomalies are detected on ultra-
sound for medical indication. Karyotyping performed after
fetal death was not considered as PND.
First prenatal test performed
For each case we determined which test was performed
first in the pregnancy: PNS1, PNS2 or PND. If PNS1
was followed by PND, PNS1 was recorded as the first
prenatal test performed, if PND was performed without
PNS1 or PNS2, PND was recorded as first prenatal test
and so on. Cases with a postnatal diagnosis and no infor-
mation on PNS or PND were classified as no ‘PNS or
PND performed’.
Time of diagnosis
The time of diagnosis was recorded as the time the
(molecular) cytogenetic diagnosis was made: prenatally
< 24 weeks, prenatally > = 24 weeks or postnatally.
Cases with specific ultrasound anomalies suspect for a
trisomy but without prenatal karyotyping and cases
with a post mortem cytogenetic diagnosis were defined
as postnatally diagnosed.
Pregnancy outcome
Pregnancy outcome was defined as fetal death (miscar-
riage and intrauterine fetal deaths after 24 weeks gesta-
tion), TOP or live birth. Live born cases, which died
after birth, were defined as live births.
Data analysis
We compared the first prenatal tests performed, time of
diagnosis and pregnancy outcome before (2005–2006)
and after implementation of the PNS (2007–2012). For
certain analyses we divided the period after implementa-
tion in 2 sub periods (2007–2009 and 2010–2012) to
investigate if a trend was present. We also stratified the
analyses between type of trisomy (T21 vs T13/T18) and
between two age categories (<=35 years and >35 years).
T13 and T18 were combined in one group as these triso-
mies have a comparable presentation in pregnancy, with
respect to the first trimester risk assessment with the
T21 algorithm [10, 11].
We compared the proportion of cases who received
PNS1, PNS2 and PND as the first test in pregnancy
between the time periods, but we also compared the
cumulative proportion of cases taking these different
types of tests: PNS1, PNS1 and/or PNS2, PNS1 and/or
PNS2 and/or PND between the time periods and stratified
for maternal age.
The data were analysed by IBM SPSS Statistics (ver-
sion 20). Chi square (X2) or Fisher Exact Test was
used to investigate whether the proportions were sta-
tistically different between the period before and after
implementation. A p-value < 0.05 (two sided) was con-
sidered a statistically significant difference.
Results
The study population consisted of 503 cases: 331 (66%)
T21, 135 (27%) T18 and 37 (7%) T13. For 53% of the
cases the mothers were over 35 years (7 cases with
missing information on maternal age). During the study
period, 141,789 children were born in the Northern
Netherlands. The total prevalence of T21 was 23.3 per
10,000 births; 13.2 per 10,000 births in women < = 35 years
and 79.4 per 10,000 birth in women >35 years.
In Table 1 results are presented on first prenatal test
performed, time of diagnosis and pregnancy outcome for
the study population, according to year of birth and fur-
ther specified according to maternal age (Table 2) and
type of common trisomies (Table 3).
Prenatal tests performed
Before implementation 62% of the cases had a PNS1,
PNS2 or PND performed, while after implementation
the proportion increased to 79% in 2007–2009 and 84%
in 2010–2012, see Table 1. This increase is mainly due
to the higher uptake of PNS2 after the implementation,
while the uptake of PND without prior screening tests
decreased (p < 0.01).
Table 2 and Fig. 1 also point to difference between the
age groups. In general, PNS1 was more frequently per-
formed in women >35 years, than in women < =35 years:
56% versus 25%. This difference was observed before
and after implementation, but with an increase in PNS1
performed in women >35 year from 54% in 2007–2009
to 62% in 2010–2012. After the implementation, the
proportion of women < =35 years that had a screening
test performed in their pregnancy (PNS1, PNS2 or both)
was 70, and 75% of the women >35 years. Prenatal diag-
nosis without prior screening decreased in the group
women < =35 year from 20% before to 5% after imple-
mentation and in the group women over 35 years and
older from 25 to 14% (Table 2).
Time of diagnosis
In 60% of the total cohort the diagnosis was made pre-
natally. This percentage did not change over time,
although the proportion of cases that was diagnosed
<24 weeks increased from 50% before to 57% after
implementation (Table 1, (p = 0.054). Overall, in the age
group < =35 years the diagnosis was made prenatally in
47% of cases, while in the age group >35 years the diag-
nosis was made prenatally in 73% of cases (p < 0.01).
Although, in both maternal age groups the proportion of
cases diagnosed postnatally remained similar after the
implementation, there was a shift in timing of the pre-
natally diagnosed cases in the group < =35 year. In this
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age group, 30% were detected before 24 weeks of gesta-
tion before implementation; after implementation this
proportion increased to 43% (p = 0.09, Table 2). T21 was
less frequently diagnosed prenatally than T13/T18, but
no shift occurred in time of diagnosis of T21 (p = 0.885,
Table 3). However, for the T13/T18 cases the diagnosis
was made earlier with more cases detected before
24 weeks of gestation 62% before versus 84% after
implementation (p < 0.01, Table 3). The majority of the
diagnosis in T13/T18 cases was made before 18 weeks
gestation, but the proportion diagnosed before 18 weeks
did not increase in 2010–2012 (54%) compared to
2005–2006 (49%) and 2007–2009 (61%). There was an
increase in the proportion diagnosed between 18 and 23
weeks, from 13% in 2005–2006 to 30% in 2010–2012.
Pregnancy outcome
After implementation of the PNS no significant shift
occurred in pregnancy outcome (p = 0.913) compared to
the period before implantation in the entire cohort
(Table 1). Termination of pregnancy was performed in
87% of the prenatally diagnosed cases.
No significant shift occurred in pregnancy outcome in
both maternal age groups since the implementation of
PNS. But, overall, in the group < =35 year more children
with trisomies were live born: 56% versus 28% in
women >35 years, whereas in the group >35 year more
pregnancies were terminated: 61% compared to 33%,
Table 2 (p < 0.01).
In the T13/T18 group the percentage of fetal deaths
decreased since the implementation from 26 to 15% and
the percentage of TOPs increased from 55 to 72%
(Table 3). This shift in pregnancy outcomes was however
not statistically significant (p = 0.112).
Discussion
In this population based study on prenatal detection of
common trisomies after the introduction of a nationwide
prenatal screening program, we found a shift in the pro-
portion of women that had PNS performed, mainly due
to an increase in the 20 weeks scan (PNS2). As a conse-
quence more diagnoses were made earlier in pregnancy
(<24 weeks) although the overall proportion of pre-
natally diagnosed cases remained at about 60% before
and after implementation. However, there is a difference
in time of diagnosis between both age groups: in women
>35 years the diagnosis was made more often prenatally
than in women < =35 years, which resulted in more
TOPs among women of >35 years. The T13/T18 diagno-
sis is made earlier in pregnancy and in T13/T18 preg-
nancies fetal deaths decreased while TOPs increased.
The aim of the study was not to evaluate the per-
formance of the PNS program but to evaluate the
impact of the implementation of a nationwide program
for PNS on the time of detection of common trisomies
and subsequent pregnancy outcome. Although we
could not cover the whole of the Netherlands in this
study, we were able to include every recognized com-
mon trisomy case in the Northern Netherlands. The
Table 1 First prenatal test, time of diagnosis and pregnancy outcome according to year of birth in cases with a common trisomy
(T21, T18, T13)
Year of birth
2005–2006 2007–2009 2010–2012 Total
First prenatal test*
PNS1 47 37% 72 39% 87 46% 206 41%
PNS2 4 3% 52 28% 57 30% 113 22%
PND 29 23% 23 12% 14 7% 66 13%
No PNS or PND 48 38% 40 21% 30 16% 118 23%
Time of diagnosis**
Postnatally 52 41% 79 42% 71 38% 202 40%
Prenatally < 24 weeks 64 50% 104 56% 108 57% 276 55%
Prenatally > = 24 weeks 12 9% 4 2% 9 5% 25 5%
Pregnancy outcome***
Live birth 55 43% 79 42% 76 40% 210 42%
Fetal death 14 11% 15 8% 24 13% 53 11%
TOP 59 46% 93 50% 88 47% 240 48%
T21 trisomy 21, T18 trisomy 18, T13 trisomy 13, PNS1 prenatal screening in first trimester, PNS2 prenatal screening in second trimester, PND prenatal diagnosis,
TOP termination of pregnancy
*X2 = 60.2, p < 0.001; X2 for trend = 23.5, p < 0.01
**X2 = 9.3, p = 0.054
***X2 = 2.4, p = 0.658
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cytogenetic laboratory is the only laboratory in the re-
gion which performs these tests. Therefore we consider
this study truly population based. Only cases, that were
not karyotyped, could theoretically have been missed.
We were not able to find out in every case if PNS was
performed or not. Some cases would not have had per-
formed PNS at all. Cases with only prenatal diagnosis
for AMA and some fetal deaths could not have a PNS2
because the pregnancy was terminated or lost before
the second trimester. Therefore both the uptake of PNS
and PND were used in order to determine for which
prenatal care the pregnant women opted first.
We included also PNS2 as a screening method for
common trisomies. The detection of softmarkers and
certain anomalies during PNS2 may indicate the presence
of T21, T13 or T18, leading to an AC or CVS. In addition,
PNS1 and PNS2 were both implemented as a part of the
nation wide Dutch prenatal screening program at the
same time in 2007 and therefore the influence of both is
important leading to the detection of common trisomies.
Before 2007, PNS was not carried out nation wide, but
was nevertheless performed on individual basis. In the
Table 2 First prenatal test, time of diagnosis and pregnancy
outcome according to year of birth in cases with a common
trisomy (T21, T18, T13) in women < =35 years and >35 years
Year of birth
2005–2006 2007–2012 Total
Women < = 35 years N = 61 N = 169 N = 230
First prenatal test**
PNS1 15 25% 42 25% 57 25%
PNS2 1 2% 76 45% 77 33%
PND 12 20% 9 5% 21 9%
No PNS or PND 33 54% 42 25% 75 33%
Time of diagnosis**
Postnatal 34 56% 89 53% 123 53%
Prenatal < 24 weeks 18 30% 73 43% 91 40%
Prenatal > = 24 weeks 9 15% 7 4% 16 7%
Pregnancy outcome
Live birth 34 56% 94 56% 128 56%
Fetal death 8 13% 17 10% 25 11%
TOP 19 31% 58 34% 77 33%
Women >35 years* N = 67 N = 199 N = 266
First prenatal test**
PNS1 32 48% 116 58% 148 56%
PNS2 3 4% 33 17% 36 14%
PND 17 25% 28 14% 45 17%
No PNS or PND 15 22% 22 11% 37 14%
Time of diagnosis
Postnatal 18 27% 54 27% 72 27%
Prenatal < 24 weeks 46 69% 139 70% 185 70%
Prenatal > = 24 weeks 3 4% 6 3% 9 3%
Pregnancy outcome
Live birth 21 31% 54 27% 75 28%
Fetal death 6 9% 22 11% 28 11%
TOP 40 60% 123 62% 163 61%
T21 trisomy 21, T18 trisomy 18, T13 trisomy 13, PNS1 prenatal screening in first
trimester, PNS2 prenatal screening in second trimester, PND prenatal diagnosis,
TOP termination of pregnancy
*7 cases with missing maternal age: all came from period 2007–2012, 1 case
performed PNS1 and 6 had no known PNS or PND, all had a postnatal
diagnosis of T21 and were live births
**p < 0.05
Table 3 First prenatal test, time of diagnosis and pregnancy
outcome according to year of birth in cases with a common
trisomy (T21, T18, T13) in cases with T21 and cases with T13/18
Year of birth
2005–2006 2007–2012 Total
Trisomy 21 N = 81 N = 250 N = 331
First prenatal test*
PNS1 28 35% 93 37% 121 37%
PNS2 2 2% 82 33% 84 25%
PND 11 14% 16 6% 27 27%
No PNS or PND 40 49% 59 24% 99 30%
Time of diagnosis
Postnatal 44 54% 134 54% 178 54%
Prenatal < 24 weeks 35 43% 107 43% 142 43%
Prenatal > = 24 weeks 2 2% 9 4% 11 3%
Pregnancy outcome
Live birth 46 57% 139 56% 185 56%
Fetal death 2 2% 20 8% 22 7%
TOP 33 41% 91 36% 124 37%
Trisomy 13 and 18 N = 47 N = 125 N = 172
First prenatal test*
PNS1 19 40% 66 53% 85 49%
PNS2 2 4% 27 22% 29 17%
PND 18 38% 21 17% 39 23%
No PNS or PND 8 17% 11 9% 19 11%
Time of diagnosis*
Postnatal 8 17% 16 13% 24 14%
Prenatal < 24 weeks 29 62% 105 84% 134 78%
Prenatal > = 24 weeks 10 21% 4 3% 14 8%
Pregnancy outcome
Live birth 9 19% 16 13% 25 15%
Fetal death 12 26% 19 15% 31 18%
TOP 26 55% 90 72% 116 67%
T21 trisomy 21, T18 trisomy 18, T13 trisomy 13, PNS1 prenatal screening in first
trimester, PNS2 prenatal screening in second trimester, PND prenatal diagnosis,
TOP termination of pregnancy
*p < 0.05
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Northern Netherlands a second trimester serum screening
has been offered on research basis since the 1990’s, but
implementation was not supported nationwide by the
Dutch Society of Obstetrics and Gynaecology [1]. Since
the end of the 1990’s “scans for keepsake” were offered,
without counselling about the possibility of the detection
of fetal anomalies. The Dutch Health Council set the con-
dition that quality of the counselling and the ultrasound
performance should be guaranteed for SAS [12]. There-
fore ultrasounds performed before 2007 were not con-
sidered as PNS2 in this study. Since the implementation,
the quality of the SAS units is guaranteed and periodically
audited by the regional screening centers which are
orchestrated by the National Institute for Public Health
and Environment. Information on PNS2 can be missing if
there was only data from the laboratory available. There-
fore the differences between the period before and the
period after implementation might be less pronounced.
The uptake for PNS by pregnant women in the Northern
Netherlands is estimated 17% for PNS1 risk assessment
and 85% for PNS2 by SAS since the implementation [13].
Although the use standardized educational materials is
mandatory in the counselling, the uptake for PNS1 in the
Northern Netherlands is relatively low compared to the
South-Western part of the Netherlands (28%) [14] and to
other countries with uptakes reported between 48 and 97%
[10, 15, 16]. These findings stress the importance of
adequate counselling in which not only information is
given about the conditions that are screened for and the
tests that can be done, but also decision making support is
provided by the counsellor to allow the woman to make an
informed choice [17]. Different factors e.g., socio-economic
status, attitude towards Downs’ syndrome and TOP, coun-
selling, costs and knowledge about first trimester prenatal
screening can influence the uptake. In the Northern
Netherlands the main reason for the low uptake for PNS1
is the relatively positive attitude toward Downs’ syndrome
and a negative attitude towards TOP [18]. Women of
35 years or younger tend to decline PNS1. The fact that
the costs were not covered by the health insurance in this
group may also have played a role. In our cohort the pro-
portion of women that had PNS1 and/or PNS2 performed
was similar in women < =35 and >35 years after the imple-
mentation of PNS. In other European countries several
fetal scans are offered on a regular basis [19], while in the
Netherlands SAS is offered after counselling and women
are free to refrain from PNS2. If a SAS is not performed, as
was the case before implementation, polyhydramnion,
growth restriction or maternal symptoms in T18 and 13
becomes more evident in the 3rd trimester.
No shift occurred in the time of detection (prenatally
vs. postnatally) or pregnancy outcome since the imple-
mentation of prenatal screening, in contrast to many
other countries where prenatal detection of common
trisomies has increased and the live birth rate has
decreased [2–6]. The relatively low uptake of PNS1 and
the low prevalence of ultrasound anomalies in T21is
the most likely explanation for the fact that the imple-
mentation of a nationwide PNS did not impact the pre-
natal detection and pregnancy outcome on a population
level in the Northern Netherlands.
Although T13/T18 show more often ultrasound
anomalies, still 14% was only detected postnatally in
this study. A possible explanation could be that we con-
sidered diagnosis made after fetal deaths as postnatally
diagnosed cases. Although no shift in prenatal or postnatal
detection occurred, the implementation was accompanied
with an increased proportion of cases diagnosed before
24 weeks. Detection before 24 weeks of pregnancy is
important given the legal limit for TOP in the Netherlands
of 24 weeks’ gestation. Interestingly, the main contributor
to earlier diagnosis of T18 and T13 (<24 weeks) was
the introduction of the routine 20 weeks scan, whose
uptake is high.
Since April 2014, cell free (cf ) DNA testing for T21,
T13 and T18 has become available in the Netherlands as
part of a national implementation research study: Trial
by Dutch Laboratories for Evaluation of Non-Invasive
Prenatal Testing (TRIDENT study) [20]. Women with
an increased risk for trisomies (after a combined test, or
Fig. 1 First prenatal test performed in cases with a common trisomy according to year of birth and maternal age. Abbreviations: PNS1 prenatal
screening in first trimester, PNS2 prenatal screening in second trimester, PND prenatal diagnosis
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because of a previous affected pregnancy) are offered
this test. Since the introduction of cfDNA testing as sec-
ond-tier test the number of invasive tests has decreased
[21]. The availability of cfDNA testing as alternative to the
CT, may lead to a higher uptake of prenatal screening [22]
which may lead to a more pronounced effect on the out-
come of pregnancies affected with a common trisomy
than found in this study.
Conclusion
This study showed that if the uptake of prenatal screening
for chromosomal anomalies is low, the introduction of a
national screening program has limited impact on the
time of detection and outcome of the most common triso-
mies 21, 18 and 13. However, a low impact should not be
mistaken for a low performance of the prenatal screening
progam, as performance is measured by detection rate
and false positive rate which we could not calculate with
the available data. The uptake of the structural anomaly
scan (PNS2) was much higher than of first trimester
screening (PNS1). As a consequence more diagnoses were
made < 24 weeks, but the overall proportion of prenatally
diagnosed cases remained unchanged at about 60% before
and after implementation. The only difference in time of
diagnosis occurred in women >35 years, where the diag-
nosis was made more often prenatally leading to more
TOP, than in women < =35 years. Owing to the overall
higher rate of prenatally diagnosed T18 and 13 < 24 weeks,
there was a shift from less fetal deaths to more TOPs.
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diagnosis; PNS: Prenatal screening; PNS1: Prenatal screening in first trimester;
PNS2: Prenatal screening in second trimester; QF-PCR: Quantitative
fluorescence-polymerase chain reaction; SAS: Structural anomaly scan;
T13: Trisomy 13; T18: Trisomy 18; T21: Trisomy 21; TOP: Termination of
pregnancy; TRIDENT: Trial by Dutch laboratories for evaluation of non-
invasive prenatal testing; UMCG: University Medical Centre Groningen;
X2: Chi square
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